Long-term outcomes after an aggressive resection of adenosquamous carcinoma of the pancreas

  • Takaaki ItoEmail author
  • Teiichi Sugiura
  • Yukiyasu Okamura
  • Yusuke Yamamoto
  • Ryo Ashida
  • Katsuhisa Ohgi
  • Keiko Sasaki
  • Katsuhiko Uesaka
Original Article



Adenosquamous carcinoma (ASC) of the pancreas is a rare malignancy, associated with a poor prognosis after surgical resection, with reported median survival times (MSTs) ranging from 4.4 to 13.1 months. We conducted this study to investigate the long-term outcomes of patients after the resection for ASC.


Between 2002 and 2016, a total of 456 patients underwent resection for ASC or adenocarcinoma (AC) of the pancreas. ASC was confirmed in 17 (3.7%) of these patients. We analyzed the clinicopathological characteristics and survival of these 17 patients in comparison with those of patients with AC of the pancreas.


The operative procedures performed were pancreaticoduodenectomy (n = 6) and distal pancreatectomy (n = 11). Seven (41.2%) of the 17 patients underwent combined organ resection. R0 resection was achieved in 16 (94.1%) patients. The 5-year overall survival (OS) rate and MST were 40.3% and 20.9 months, respectively. A squamous component of ≥ 60% (P = 0.001) and R1 resection (P < 0.001) were significantly associated with poor OS for patients with ASC


This study revealed longer survival and a higher R0 resection rate after aggressive combined resection in our ASC patients than those in previous studies. Although this was only a small series, our findings suggest that local control with aggressive resection may be an effective treatment protocol for ASC patients.


Pancreatic cancer Adenosquamous carcinoma Combined resection 


Compliance with ethical standards

Conflict of interest

Takaaki Ito and his co-authors have no conflicts of interest to declare.


  1. 1.
    Capussotti L, Massucco P, Ribero D, Vigano L, Muratore A, Calgaro M (2003) Extended lymphadenectomy and vein resection for pancreatic head cancer: outcomes and implications for therapy. Arch Surg 138:1316–1322CrossRefGoogle Scholar
  2. 2.
    Wray CJ, Ahmad SA, Matthews JB, Lowy AM. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology. 2005;128:1626–41.CrossRefGoogle Scholar
  3. 3.
    Yamada S, Fujii T, Sugimoto H, Nomoto S, Takeda S, Kodera Y, et al. Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines. Pancreas. 2013;42:1004–100.CrossRefGoogle Scholar
  4. 4.
    Katz MH, Taylor TH, Al-Refaie WB, Hanna MH, Imagawa DK, Anton-Culver H, et al. Adenosquamous versus adenocarcinoma of the pancreas: a population-based outcomes analysis. J Gastrointest Surg. 2011;15:165–74.CrossRefGoogle Scholar
  5. 5.
    Boyd CA, Benarroch-Gampel J, Sheffield KM, Cooksley CD, Riall TS. 415 patients with adenosquamous carcinoma of the pancreas: a population-based analysis of prognosis and survival. J Surg Res. 2012;174:12–9.CrossRefGoogle Scholar
  6. 6.
    Madura JA, Jarman BT, Doherty MG, Yum MN, Howard TJ (1999) Adenosquamous carcinoma of the pancreas. Arch Surg. 134:599–603CrossRefGoogle Scholar
  7. 7.
    Hsu JT, Chen HM, Wu RC, Yeh CN, Yeh TS, Hwang TL, et al. Clinicopathologic features and outcomes following surgery for pancreatic adenosquamous carcinoma. World J Surg Oncol. 2008;6:95.CrossRefGoogle Scholar
  8. 8.
    Smoot RL, Zhang L, Sebo TJ, Que FG. Adenosquamous carcinoma of the pancreas: a single-institution experience comparing resection and palliative care. J Am Coll Surg. 2008;207:368–70.CrossRefGoogle Scholar
  9. 9.
    Voong KR, Davison J, Pawlik TM, Uy MO, Hsu CC, Winter J, et al. Resected pancreatic adenosquamous carcinoma: clinicopathologic review and evaluation of adjuvant chemotherapy and radiation in 38 patients. Hum Pathol. 2010;41:113–22.CrossRefGoogle Scholar
  10. 10.
    Simone CG, Zuluaga Toro T, Chan E, Feely MM, Trevino JG, George TJ Jr. Characteristics and outcomes of adenosquamous carcinoma of the pancreas. Gastrointestinal cancer research : GCR. 2013;6:75–9.Google Scholar
  11. 11.
    Kardon DE, Thompson LD, Przygodzki RM, Heffess CS. Adenosquamous carcinoma of the pancreas: a clinicopathologic series of 25 cases. Gastrointest Cancer Res GCR. 2001; 14:443-51.Google Scholar
  12. 12.
    Hester CA, Augustine MM, Choti MA, Mansour JC, Minter RM, Polanco PM, et al. Comparative outcomes of adenosquamous carcinoma of the pancreas: an analysis of the National Cancer Database. J Surg Oncol. 2018;118:21–30.CrossRefGoogle Scholar
  13. 13.
    Yamamoto T, Sugiura T, Mizuno T, Okamura Y, Aramaki T, Endo M, et al. Preoperative FDG-PET predicts early recurrence and a poor prognosis after resection of pancreatic adenocarcinoma. Ann Surg Oncol. 2015;22:677–84.CrossRefGoogle Scholar
  14. 14.
    Ito T, Sugiura T, Okamura Y, Yamamoto Y, Ashida R, Aramaki T et al (2017) The diagnostic advantage of EOB-MR imaging over CT in the detection of liver metastasis in patients with potentially resectable pancreatic cancer. Pancreatology. 17:451–456CrossRefGoogle Scholar
  15. 15.
    Sugiura T, Okamura Y, Ito T, Yamamoto Y, Uesaka K. Surgical indications of distal pancreatectomy with celiac axis resection for pancreatic body/tail cancer. World J Surg. 2017;41:258–66.CrossRefGoogle Scholar
  16. 16.
    Sugiura T, Uesaka K, Mihara K, Sasaki K, Kanemoto H, Mizuno T, et al. Margin status, recurrence pattern, and prognosis after resection of pancreatic cancer. Surgery. 2013;154:1078–86.CrossRefGoogle Scholar
  17. 17.
    Sobin L, Gospodarowicz M, Wittekind C (2009) TNM classification of malignant tumors, 7th edn. Wiley, New YorkGoogle Scholar
  18. 18.
    Hoshimoto S, Hoshi N, Hishinuma S, Shirakawa H, Tomikawa M, Ozawa I et al (2017) Clinical implications of the proliferative ability of the squamous component regarding tumor progression of adenosquamous carcinoma of the pancreas: a preliminary report. Pancreatology. 17:788–794CrossRefGoogle Scholar
  19. 19.
    Solaini L, de Rooij T, Marsman EM, Te Riele WW, Tanis PJ, van Gulik TM, et al. Pancreatoduodenectomy with colon resection for pancreatic cancer: a systematic review. HPB. 2018;20:881–7.CrossRefGoogle Scholar
  20. 20.
    Hong SM, Kim MJ, Jang KT, Yoon GS, Cho H, Frierson HF, et al. Adenosquamous carcinoma of extrahepatic bile duct: clinicopathologic study of 12 cases. Int J Clin Exp Pathol. 2008;1:147–56.Google Scholar
  21. 21.
    Komatsu H, Egawa S, Motoi F, Morikawa T, Sakata N, Naitoh T, et al. Clinicopathological features and surgical outcomes of adenosquamous carcinoma of the pancreas: a retrospective analysis of patients with resectable stage tumors. Surg Today. 2015;45:297–304.CrossRefGoogle Scholar
  22. 22.
    Imaoka H, Shimizu Y, Mizuno N, Hara K, Hijioka S, Tajika M et al (2014) Ring-enhancement pattern on contrast-enhanced CT predicts adenosquamous carcinoma of the pancreas: a matched case–control study. Pancreatology. 14:221–226CrossRefGoogle Scholar
  23. 23.
    Toshima F, Inoue D, Yoshida K, Yoneda N, Minami T, Kobayashi S, et al. Adenosquamous carcinoma of pancreas: CT and MR imaging features in eight patients, with pathologic correlations and comparison with adenocarcinoma of pancreas. Abdom Radiol (New York). 2016;41:508–20.CrossRefGoogle Scholar
  24. 24.
    Okabayashi T, Hanazaki K. Surgical outcome of adenosquamous carcinoma of the pancreas. World J Gastroenterol. 2008;14:6765–70.CrossRefGoogle Scholar
  25. 25.
    Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K et al (2007) Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama. 297:267–277CrossRefGoogle Scholar
  26. 26.
    Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. Jama. 2013;310:1473–81.CrossRefGoogle Scholar
  27. 27.
    Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet (London, England). 2016;388:248–57.CrossRefGoogle Scholar
  28. 28.
    Yamaguchi K, Okusaka T, Shimizu K, Furuse J, Ito Y, Hanada K, et al. Clinical practice guidelines for pancreatic cancer 2016 from the Japan Pancreas Society: a synopsis. Pancreas. 2017;46:595–604.CrossRefGoogle Scholar
  29. 29.
    Wild AT, Dholakia AS, Fan KY, Kumar R, Moningi S, Rosati LM, et al. Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas. J Gastrointest Oncol. 2015;6:115–25.Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Division of Hepato-Biliary-Pancreatic SurgeryShizuoka Cancer Center HospitalShizuokaJapan
  2. 2.Division of Diagnostic PathologyShizuoka Cancer Center HospitalShizuokaJapan

Personalised recommendations